Ruane, Cunniff & Goldfarb L.P.: ELEVANCE HEALTH INC (ELV): Quarterly 13F Position History
As of Q1 2026, Ruane, Cunniff & Goldfarb L.P. reported 1,387,968 shares of ELEVANCE HEALTH INC (ELV), worth $406.3M and representing 6.7% of its 13F equity book. Quarter-over-quarter share count change: 34,538 (-2.4%) . The position first appeared in Q1 2021 and has been disclosed across 21 13F-HR filings in Pactolio's tracked window.
- 1,387,968Shares Held (Latest Filing)
- $406.3MReported Market Value (Latest Filing)
- 6.7%Portfolio Weight (% of 13F Equity Book)
- 34,538Quarter-over-Quarter Share Change
- -$92.3MQuarter-over-Quarter Value Change
- 1,844,001Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 21 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,387,968 | 34,538 | -2.4% | $406.3M | 6.7% | $292.8 |
| Q4 2025 | 1,422,506 | 25,777 | -1.8% | $498.7M | 7.8% | $350.6 |
| Q3 2025 | 1,448,283 | +352,628 | +32.2% | $468.0M | 7.8% | $323.1 |
| Q2 2025 | 1,095,655 | 27,265 | -2.4% | $426.2M | 7.3% | $389.0 |
| Q1 2025 | 1,122,920 | 21,033 | -1.8% | $488.4M | 8.9% | $435.0 |
| Q4 2024 | 1,143,953 | +139,420 | +13.9% | $422.0M | 7.2% | $368.9 |
| Q3 2024 | 1,004,533 | 19,538 | -1.9% | $522.4M | 8.2% | $520.0 |
| Q2 2024 | 1,024,071 | 50,614 | -4.7% | $554.9M | 8.6% | $541.9 |
| Q1 2024 | 1,074,685 | 46,958 | -4.2% | $557.3M | 8.7% | $518.5 |
| Q4 2023 | 1,121,643 | 28,578 | -2.5% | $528.9M | 8.5% | $471.6 |
| Q3 2023 | 1,150,221 | +101,573 | +9.7% | $500.8M | 8.3% | $435.4 |
| Q2 2023 | 1,048,648 | +241,524 | +29.9% | $465.9M | 7.4% | $444.3 |
| Q1 2023 | 807,124 | 19,399 | -2.3% | $371.1M | 6.1% | $459.8 |
| Q4 2022 | 826,523 | 161,334 | -16.3% | $424.0M | 6.6% | $513.0 |
| Q3 2022 | 987,857 | 26,130 | -2.6% | $448.7M | 6.7% | $454.2 |
| Q2 2022 | 1,013,987 | 743,441 | -42.3% | $489.3M | 6.4% | $482.6 |
| Q1 2022 | 1,757,428 | 12,612 | -0.7% | $863.3M | 8.5% | $491.2 |
| Q4 2021 | 1,770,040 | 51,373 | -2.8% | $820.5M | 7.0% | $463.5 |
| Q3 2021 | 1,821,413 | 22,588 | -1.2% | $679.0M | 6.1% | $372.8 |
| Q2 2021 | 1,844,001 | +672,156 | +57.4% | $704.0M | 6.2% | $381.8 |
| Q1 2021 | 1,171,845 | — | — | $420.6M | 4.0% | $359.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Ruane, Cunniff & Goldfarb L.P. first disclose a ELV position in 13F-HR filings?
Ruane, Cunniff & Goldfarb L.P. first reported ELEVANCE HEALTH INC (ELV) on its 13F-HR filing for the period ending 2021-03-31 (Q1 2021). The position has appeared on 21 reported quarters within Pactolio's tracked window.
What was Ruane, Cunniff & Goldfarb L.P.'s most recent quarter-over-quarter share-count change in ELV?
Between Q4 2025 and Q1 2026, Ruane, Cunniff & Goldfarb L.P. reduced its ELV position by 34,538 shares (-2.4%), leaving 1,387,968 shares at a market value of $406.3M.
Does the implied price-per-share represent Ruane, Cunniff & Goldfarb L.P.'s cost basis in ELV?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.